S-1/A: Farlong Holding Files IPO Amendment Amidst Losses

Farlong Holding Corporation filed an S-1/A amendment for its initial public offering, seeking to raise $14.5 million while disclosing recurring losses and substantial doubt about its ability to continue as a going concern.

Summary

• Farlong Holding Corporation is pursuing an Initial Public Offering (IPO) of 4,000,000 shares of common stock at an estimated price of $4.00 per share, aiming to raise approximately $14.5 million in net proceeds.
• The company reported a net loss of $2,555,522 for the fiscal year ended September 30, 2025, an increase from $1,955,962 in 2024, and an accumulated deficit of $6,639,708.
• Management has identified substantial doubt about the company's ability to continue as a going concern due to recurring losses from operations and negative cash flows since 2022.
• Revenue decreased by 5.19% to $725,806 in fiscal year 2025 from $765,509 in 2024, primarily due to a strategic shift to streamline product lines and discontinue non-proprietary products.
• The DirecTCM platform, launched in May 2025, had 30,000 pre-registered healthcare providers but only 80 active providers as of September 30, 2025, generating limited subscription revenue of $1,391.
• The company is a 'controlled company' under Nasdaq rules, with Karin Mei Huang holding 90.9% of voting power through family trusts post-IPO, though it does not currently intend to rely on associated corporate governance exemptions.
• Farlong relies entirely on third-party contract manufacturers located in China for its supplement production, exposing it to significant risks from U.S. tariffs and trade disputes.
• The net proceeds from the IPO are intended for general corporate purposes, including 31% for working capital, 24% for R&D, 20% for marketing and operational expenses, 18% for infrastructure upgrades, and 7% for international expansion.

Sentiment

Score: 2

Explanation: The company faces significant financial challenges, including recurring losses, negative cash flow, and a going concern warning. While the IPO provides a capital injection and there are R&D efforts, the current financial performance and high operational risks (e.g., China manufacturing reliance, low DirecTCM adoption) indicate a very high-risk investment.

Positives

• The company is undertaking an IPO to raise approximately $14.5 million in net proceeds, which will provide much-needed capital for operations and growth initiatives.
• Farlong has a vertically integrated business model, combining traditional herbal knowledge with modern scientific techniques for product development.
• The DirecTCM platform has attracted approximately 30,000 pre-registered healthcare providers since its launch in May 2025, indicating potential for future growth in its B2B channel.
• The company has an experienced management team with strong financial and operational expertise, including CEO Jackson Kwok and CFO Chiwen Claire Wang.
• Farlong is actively investing in R&D, including preclinical studies with City of Hope for White Button Mushroom (anti-cancer), Polygonum Capitatum (anti-diabetes), and Rodgersia Sambucifolia Hemsl (inflammation support).
• The company has established a robust distribution network with three strategically located third-party warehouses in California, Texas, and New Jersey, enabling next-day delivery to most U.S. regions.
• Farlong has adopted a Clawback Policy for executive compensation and a Whistleblower Protection Policy, enhancing corporate governance.

Negatives

• Farlong has experienced significant accumulated deficits of $6,639,708 as of September 30, 2025, and recurring net losses, raising substantial doubt about its ability to continue as a going concern.
• Net loss increased by 30.65% to $2,555,522 in fiscal year 2025 from $1,955,962 in 2024.
• Revenue decreased by 5.19% to $725,806 in fiscal year 2025, indicating a decline in sales despite new product launches.
• The DirecTCM platform, a key growth strategy, had only 80 active healthcare providers (0.27% of pre-registered) and generated immaterial subscription revenue ($1,391) in fiscal year 2025.
• The company relies heavily on a small number of customers (ZenLife accounted for 21% of revenue in 2025) and vendors (five largest vendors accounted for 44%, 18%, 15%, 11%, and 10% of total purchases in 2025).
• Clinical studies to date have not shown statistically significant outcomes, and past studies' results are descriptive and hypothesis-generating rather than confirmatory of efficacy.
• Selling expenses increased by 182.43% to $450,626 in fiscal year 2025, contributing to increased losses.
• The company has identified material weaknesses in its internal control over financial reporting, including a lack of formal risk assessment policies and IT-related deficiencies.

Risks

• Significant accumulated deficits and recurring losses from operations raise substantial doubt about the company's ability to continue as a going concern.
• The company will need additional capital, which may not be available on commercially acceptable terms, if at all, leading to potential dilution for existing stockholders or jeopardizing business viability.
• Operating results may vary considerably in the future, making it challenging to forecast performance and potentially causing results to fall short of expectations.
• Failure to maintain high-quality standards for products and services could harm the business and damage its reputation, leading to recalls, negative publicity, and customer loss.
• A significant amount of revenue and purchases historically depend on a small number of customers and vendors, and the loss of any material party could adversely affect operations.
• Customer demand is difficult to forecast accurately, potentially leading to an inability to match planning and spending decisions to demand.
• Approximately 17% of revenue in FY2025 was derived from sales on Amazon and TikTok, making the company vulnerable to platform restrictions or changes in terms of service.
• Increases in ingredient costs, long lead times, supply shortages, and changes could disrupt the supply chain and negatively impact business, financial condition, and operating results.
• The company relies entirely on third-party contract manufacturers located in China, making it highly vulnerable to U.S. tariffs, trade disputes, and other disruptions related to U.S.-China trade relations, which could significantly increase costs.
• The herbal supplement industry is highly competitive, and increased competition from existing or new entrants could decrease net revenue.
• Global economic conditions, including inflation, slower growth, tariffs, and higher interest rates, could materially and adversely affect the company's business.
• The company is subject to numerous laws and regulations applicable to the herbal supplement industry (FDA, FTC, state agencies), and non-compliance or changes in policies could materially and adversely affect the business.
• Disagreements over product classifications (e.g., drug vs. dietary supplement) by regulatory agencies could delay or increase costs of offering products.
• Marketing activities are subject to strict governmental regulation, which may limit the ability to market or promote products.
• The use and handling of personal information, including health data, is regulated by HIPAA and other privacy laws, and non-compliance could result in significant liability and harm reputation.
• There has been no public market for the common stock prior to this offering, and the market price may be volatile or decline regardless of operating performance.
• New investors will experience immediate and substantial dilution in the net tangible book value of common stock purchased in this offering ($3.74 per share).
• Material weaknesses in internal control over financial reporting have been identified, and failure to remediate them could lead to inaccurate financial reporting or fraud.
• The company will incur substantial increased costs as a result of being a public company, including compliance with Sarbanes-Oxley Act.
• Failure to satisfy Nasdaq listing requirements could lead to delisting, negatively impacting stock price and liquidity.
• Management has broad discretion to determine how to use the funds raised in the offering, which may not enhance results of operations or stock price.
• As a controlled company, Farlong is allowed to follow certain exemptions from corporate governance requirements, which could adversely affect public stockholders.
• Nasdaq may apply additional and more stringent criteria for initial and continued listing due to the relatively small public offering and high insider ownership.
• The existence of authorized but unissued preferred stock, which can be designated by the board without stockholder approval, could cause substantial dilution or have anti-takeover effects.
• Anti-takeover provisions in corporate documents and Nevada law might discourage, delay, or prevent a change in control.
• The sale of a significant number of shares by existing stockholders after lock-up expiration could cause the market price of common stock to drop significantly.
• Cybersecurity risks could adversely affect the business and disrupt operations, as evidenced by a recent incident at the underwriter involving exfiltrated confidential company data.

Future Outlook

The company intends to expand its DirecTCM platform and product offerings, invest further in technology and R&D, and grow its business through wider e-commerce and retail partnerships, including international expansion into Asian and European markets. It plans to continue developing BioPrecision formulations and funding studies on anti-cancer and anti-diabetes applications. Management anticipates requiring approximately $3 million of additional working capital to scale marketing programs for profitability and an additional $2 million for a full commercial rollout of international expansion.

Management Comments

• Management has determined that recurring losses from operations and negative cash flows raise substantial doubt about the company's ability to continue as a going concern.
• The decline in revenue was primarily attributable to our decision to streamline the product line by discontinuing non-proprietary products in favor of our BioPrecision formulations.
• The increase in average revenue per retail customer was attributed to the rising demand for our new products from new product mix and expanding sales channels.
• Our regulatory objective is limited to marketing our formulations in the United States as dietary supplements, for which FDA approval is neither required nor available.
• We believe our future success depends on our ability to maintain and grow the value of our brands, Dr. Herbal Well and Best Doctor Formula.
• We do not currently intend to rely on the controlled company exemptions provided under Nasdaq Marketplace Rules, but we could elect to rely on these exemptions in the future.

Industry Context

The company operates within the rapidly growing global dietary supplement market, valued at $74.3 billion in 2024 and projected to reach $170.1 billion by 2034 (9.5% CAGR). The holistic herbal supplement market specifically is expected to grow from $216 billion in 2022 to $421 billion by 2032 (6.87% CAGR). Key drivers include rising chronic disorders, busy lifestyles, and increasing consumer demand for plant-based, natural, and clean-label products. Farlong aims to differentiate itself through a vertically integrated platform combining product quality with personalized wellness solutions, competing with larger players like Throne HealthTech, Nestle Health Science, Metagenics, and Fullscript.

Comparison to Industry Standards

• The filing does not provide specific comparable company financial metrics or project results to assess Farlong's performance against global industry benchmarks.
• While the company operates in a growing market, its current revenue of $0.7 million is significantly smaller than the multi-billion dollar market leaders mentioned (e.g., Nestle Health Science, Metagenics).
• The company's gross margin of 60.31% in FY2025 is within a reasonable range for the dietary supplement industry, though the lower margin for BioPrecision products (30.48%) suggests a strategic pricing or cost structure for market entry.
• The high reliance on a few customers and suppliers, and the complete dependence on Chinese contract manufacturers, may indicate a less diversified and potentially higher-risk supply chain compared to established industry standards for larger players.

Management Changes

Corporate Governance

Legal Proceedings

• The company is currently not a party to any material legal or administrative proceeding.
• A lawsuit was filed on June 20, 2024, against Longstar and other entities by a former employee alleging $1,222,000 in unpaid compensation from 2016 to 2023. Longstar's legal counsel concluded the likelihood of liability is remote, and no loss contingency has been recorded.

Related Party Transactions

• Rent deposit of $19,500 and rent expenses of $156,650 (FY2025) paid to Longstar Healthpro Manufacturing Inc., which is majority owned by Xinjiang Lixing Investment and Management Co., a former stockholder of Longstar and under common control of Karin Mei Huang.
• Accounts payable of $60,441 (FY2025) to Yunnan Panlong Yunhai Pharmaceutical Co., Ltd. for purchased products, where Ms. Lihua Zeng (sister of Lipin Zeng, Karin Mei Huang's husband) owns 30% ownership interests.
• Accounts payable of $781,668 (FY2025) to Kunming Aoqun Bio-Tech Co., Ltd. for purchased products, where Ms. Lihua Zeng serves as a director.
• Accounts payable of $23,390 (FY2025) to Yunnan Panlong Yunhai Pharmaceutical Trading Co., Ltd. for purchased products, which is a wholly owned subsidiary of Yunnan Panlong Yunhai Pharmaceutical Co., Ltd.
• Long-term loans from Karin Mei Huang (a stockholder) totaling $4,600,000 as of September 30, 2025, at an annual interest rate of 9.5%. This includes a $1,000,000 loan (Sept 2024), a $1,600,000 loan (March 2025), and a $2,000,000 loan (Sept 2025).
• Accrued loan interest of $131,933 (FY2025) owed to Karin Mei Huang.
• Purchases of products from Kunming Aoqun Bio-Tech Co., Ltd. amounted to $131,148 (FY2025) and $815,172 (FY2024).
• Purchases of inventories from Yunnan Panlong Yunhai Pharmaceutical Trading Co., Ltd. amounted to $23,390 (FY2025).
• Share-for-Share Exchange on December 27, 2023, where Karin Mei Huang exchanged 100% of Longstar's equity for 40,000,000 shares of Farlong's common stock.
• Asset Transfer Agreement on December 31, 2022, where Longstar repurchased shares from Xinjiang Lixing (a related party) through non-monetary transactions.

Stakeholder Impact

• **Shareholders (Existing & New):** Existing shareholders will experience significant dilution from the IPO. New investors face immediate and substantial dilution ($3.74 per share). The company's 'controlled company' status means Karin Mei Huang will retain significant voting power (90.9%), potentially limiting influence for other shareholders. Recurring losses and going concern doubt pose a high risk to investment value.
• **Employees:** The company plans to hire eight field sales representatives and increase internal software engineers, indicating potential job growth. However, the overall financial instability and cost-cutting measures mentioned in the going concern discussion could pose risks to job security if profitability is not achieved.
• **Customers:** The strategic shift to BioPrecision formulations and expansion of sales channels aim to improve product offerings and accessibility. However, reliance on a few key customers and potential supply chain disruptions (e.g., tariffs on Chinese manufacturers) could impact product availability or pricing. The DirecTCM platform's low active user rate suggests limited immediate impact for most pre-registered healthcare providers.
• **Suppliers:** The company's heavy reliance on a few key suppliers, particularly those in China, exposes them to risks related to trade disputes, tariffs, and potential disruptions. Any inability of Farlong to meet payment terms due to financial instability could impact these suppliers.
• **Creditors:** Related party loans from Karin Mei Huang are substantial ($4.6 million), indicating a reliance on insider financing. The going concern warning suggests increased risk for any external creditors.

Next Steps

• Complete the Initial Public Offering and list common stock on the Nasdaq Capital Market under the symbol AFA.
• Utilize IPO net proceeds for general corporate purposes, including working capital, R&D, marketing, infrastructure upgrades, and international expansion.
• Continue expanding services on the DirecTCM platform and promoting BioPrecision products.
• Invest further in technology and R&D, including refining supplement recommendation methods and conducting ongoing studies on anti-cancer and anti-diabetes applications.
• Enhance product variety and optimize sales on online platforms like Amazon, TikTok, and Walmart.com.
• Explore export opportunities for DirecTCM platform services and products in Asian and European markets.
• Remediate identified material weaknesses in internal control over financial reporting by hiring qualified accounting personnel and implementing training programs.
• Begin monthly interest payments on related party loans from Karin Mei Huang starting March 26, 2026, April 1, 2026, and October 1, 2026.

Key Dates

Recommendation

Farlong Holding Corporation presents a high-risk investment profile. The company has a history of recurring net losses, negative operating cash flows, and a significant accumulated deficit, leading to a 'substantial doubt about its ability to continue as a going concern.' While the IPO aims to raise capital, the immediate and substantial dilution for new investors ($3.74 per share on a $4.00 IPO price) is concerning. Revenue is declining, and key growth initiatives like the DirecTCM platform show very low active user engagement despite a large pre-registered base. The company's complete reliance on Chinese contract manufacturers exposes it to significant geopolitical and supply chain risks. Furthermore, the 'controlled company' status, with a single individual holding over 90% of voting power, limits corporate governance protections for public shareholders. The preclinical R&D, while positive, has not yet yielded statistically significant results. Given these severe financial and operational risks, a seasoned investor would likely recommend selling any existing shares or avoiding investment in this IPO.

Keywords

Herbal Supplements, Dietary Supplements, IPO, S-1/A, Farlong Holding Corporation, DirecTCM, Traditional Chinese Medicine, Nutraceuticals, GRAS, Nasdaq Listing, Bioprecision Formulations, Health and Wellness, Contract Manufacturing, SEC Filing, Going Concern